JHS Svendgaard Laboratories Limited has completed the conversion of warrants into equity shares, marking a significant milestone in its capital restructuring process. The company's Board of Directors approved the allotment of 18,01,801 equity shares on February 01, 2026, following the successful conversion of an equal number of warrants.

Warrant Conversion Details

The conversion involved warrants originally issued on August 03, 2024, at an issue price of Rs. 27.75 per warrant. The Board approved the allotment of equity shares with a face value of Rs. 10.00 each at the same issue price of Rs. 27.75, including a premium of Rs. 17.75 per share.

Allottee Information

Coeus Global Opportunities Fund was the sole beneficiary of this warrant conversion, receiving the entire allocation of 18,01,801 equity shares. The fund paid the balance amount of Rs. 3,74,99,983.31, representing 75% of the total issue price, as required under SEBI regulations.

Impact on Share Capital

Following this allotment, JHS Svendgaard Laboratories' paid-up equity share capital has increased to Rs. 87,40,57,670, now comprising 8,74,05,767 equity shares of Rs. 10.00 face value each. The newly issued shares carry the same rights and privileges as existing equity shares of the company.

Regulatory Compliance

The warrant conversion was conducted in accordance with SEBI (ICDR) Regulations, 2018, and the company has fulfilled all disclosure requirements under Regulation 30 of SEBI Listing Regulations. The Board meeting, which commenced at 10:00 A.M. and concluded at 10:23 A.M., ensured all procedural requirements were met for this preferential allotment on a private placement basis.

JHS Svendgaard Laboratories Limited , a company listed on Indian stock exchanges, has taken a significant step towards employee engagement and retention. The company's Nomination and Remuneration Committee has approved the grant of 31,30,000 employee stock options (ESOPs) under its newly introduced Employee Stock Option Scheme-2025.

Key Details of the ESOP Grant

Vesting and Exercise Details

The approved ESOP scheme includes the following vesting and exercise provisions:

• Vesting Period: Commences one year from the grant date and extends up to five years
• Exercise Period: Maximum of 5 years from the respective vesting date
• Special Provisions: In case of death or permanent disability of a grantee, the minimum one-year vesting period is waived

Compliance and Regulatory Aspects

The company has confirmed that the ESOP scheme is in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. This grant of ESOPs was disclosed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Implications for Employees and Shareholders

The introduction of this ESOP scheme represents a strategic move by JHS Svendgaard Laboratories to align employee interests with those of the company and its shareholders. By offering equity participation, the company aims to motivate and retain key talent, potentially leading to improved performance and long-term value creation.

For existing shareholders, while there may be a potential dilution effect in the future when these options are exercised, the alignment of employee interests with company performance could potentially offset this through improved corporate results.

As the vesting period extends over several years, the full impact of this ESOP grant on the company's financial statements and share structure will unfold gradually. Investors and stakeholders may want to monitor future financial reports for updates on the scheme's implementation and its effects on the company's performance and equity structure.